Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | STING1 | Q86WV6 | 2/20 | 0.42 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.42 |
| ▸ | GSK3A | P49840 | 1/20 | 0.41 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.41 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.41 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.41 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | AHCY | P23526 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20059072 | 1.00 | TYMP (0.50) | TYMPLMNASTING1ABCB1GSK3A | |
| SCHEMBL3163915 | 0.89 | LMNA (0.53) | TYMPLMNASTING1ABCB1GSK3A | |
| SCHEMBL13970745 | 0.89 | LMNA (0.53) | TYMPLMNASTING1ABCB1GSK3A | |
| SCHEMBL3163908 | 0.89 | LMNA (0.53) | TYMPLMNASTING1ABCB1GSK3A | |
| SCHEMBL14593730 | 0.88 | LMNA (0.46) | TYMPLMNASTING1ABCB1GSK3A | |
| SCHEMBL5389035 | 0.88 | LMNA (0.46) | TYMPLMNASTING1ABCB1GSK3A | |
| SCHEMBL5389026 | 0.88 | LMNA (0.46) | TYMPLMNASTING1ABCB1GSK3A | |
| SCHEMBL20610917 | 0.87 | NT5E (0.44) | LMNANPC1POLB | |
| SCHEMBL24673394 | 0.85 | LMNA (0.46) | TYMPLMNASTING1ABCB1GSK3A | |
| SCHEMBL22798386 | 0.85 | LMNA (0.46) | TYMPLMNASTING1ABCB1GSK3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070032448-A1 | Sugar modified nucleosides as viral replication inhibitors | RIBAPHARM INC. | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032448-A1 | Sugar modified nucleosides as viral replication inhibitors | PNP, MTAP, GALE | TYMP 16/4885LMNA 4188/4885STING1 472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.